FibroGen, Inc.
NASDAQ: FGEN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thane Wettig
- Employees
- 225
- Headquarters
- San Francisco, United States
- IPO year
- 2014
- Market cap
- $36.7M
- Website
- https://www.fibrogen.com
Loading FGEN…
Loading profile data…Frequently asked questions about FGEN
What does FibroGen, Inc. (FGEN) do?
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylase...
Where does FGEN trade?
FibroGen, Inc. (FGEN) trades on the NASDAQ Global Select.
What sector is FGEN in?
FibroGen, Inc. (FGEN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of FibroGen, Inc.?
Thane Wettig is the chief executive officer of FibroGen, Inc. (FGEN).
Where is FibroGen, Inc. headquartered?
FibroGen, Inc. is headquartered in United States.
Does FGEN pay a dividend?
FibroGen, Inc. (FGEN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FGEN go public?
FibroGen, Inc. (FGEN) completed its initial public offering in 2014.